Table 1.
Summary of studies included in the meta-analysis
| Author, Year, Reference | Enrollment Period | Total Patients | Overall Follow-up, Months | Overall Weight Change, kg (SD) | Indication | Number of Patients per Indication | Weight Change per Indication, kg (SD) |
|---|---|---|---|---|---|---|---|
| Bel Lassen 2017 (19) | 2001–2012 | 225 | 26 | 1.65 (4.7) | Euthyroid | 151 | 1 (4.9) |
| Hyperthyroid | 74 | 3.1 (4.3) | |||||
| Dale 2001 (4) | 1975–1998 | 13 | 6 | 10.27 (9.23) | Hyperthyroid | 13 | 10.27 (9.23) |
| Glick 2018 (2) | 2013–2014 | 79 | 18 | 0.06 (6.9) | Unassigned | 79 | 0.06 (6.9) |
| Jonklaas 2011 (3) | 2009–2010 | 120 | 12 | 3.1 (3.3) | Euthyroid | 120 | 3.1 (3.3) |
| Kedia 2016 (20) | 2006–2014 | 291 | 36 | 2.35 (8.57) | Euthyroid | 144 | 2.57 (9.41) |
| Cancer | 147 | 2.21 (7.77) | |||||
| Kormas 1998 (18) | Not reported | 8 | 12 | 0.5 (2.3) | Euthyroid | 8 | 0.5 (2.3) |
| Lang 2016 (7) | 2010–2013 | 581 | 12 | 1.16 (3.3) | Euthyroid | 581 | 1.16 (3.3) |
| Lombardi 2017 (21) | 2014–2015 | 155 | 2 | 0.16 (0.43) | Euthyroid | 155 | 0.16 (0.43) |
| Ozdemir 2010 (5) | 2006–2007 | 22 | 6 | 2 (2.5) | Euthyroid | 22 | 2 (2.5) |
| Polotsky 2012 (9) | 1995–2006 | 153 | 48 | 2.7 (4.6) | Cancer | 153 | 2.7 (4.6) |
| Rotondi 2014 (12) | 2005–2012 | 267 | 9 | 1.6 (4.1) | Euthyroid | 118 | 1.5 (4.1) |
| Cancer | 41 | 1.5 (4) | |||||
| Hyperthyroid | 108 | 1.7 (4.2) | |||||
| Schneider 2014 (22) | 2007–2012 | 204 | 13 | 4.7 (1) | Hyperthyroid | 204 | 4.7 (1) |
| Singh Ospina 2018 (23) | 2003–2006 | 157 | 36 | 0.32 (7.18) | Euthyroid | 7 | 2.76 (3.43) |
| 2000–2012 | Cancer | 150 | 0.15 (7.27) | ||||
| Sohn 2015 (10) | 2008 | 700 | 42 | 0.5 (3.1) | Cancer | 700 | 0.5 (3.1) |
| Tigas 2000 (8) | 1996–2000 | 57 | 16 | 6.1 (5.45) | Cancer | 25 | 0.6 (3) |
| Hyperthyroid | 32 | 10.4 (6.78) | |||||
| Weinreb 2011 (24) | Not reported | 102 | 99 | 1.51 (7.8) | Cancer | 102 | 1.51 (7.8) |
| Zihni 2017 (6) | 2011–2012 | 30 | 12 | 1.6 (3.8) | Euthyroid | 30 | 1.6 (3.8) |
Abbreviation: SD, standard deviation.